# Risk: __Development of drugs__ (PBN__Risk_431)

## Property: has_RiskISO_Impact

* [Innovation, Creativity and research](../RiskISO/PBN__RiskISO_Purpose_2)

## Property: has_RiskTechnology

* [research on potential therapeutic options](../Technology/PBN__Technology_1962)
* [clinical trials](../Technology/PBN__Technology_1961)

## Property: has_RiskSubject

* [healthcare providers](../Stakeholder/PBN__Stakeholder_121)
* [patients](../Stakeholder/PBN__Stakeholder_31)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskISO_Purpose

* [Innovation, Creativity and research](../RiskISO/PBN__RiskISO_Impact_8)

## Property: has_RiskOwner

* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)
* [scientists](../Stakeholder/PBN__Stakeholder_46)

## Property: has_RiskMitigation

* [Drug development](../RiskMitigation/PBN__RiskMitigation_599)
* [Continued research and development of drugs for the treatment of COVID-19.](../RiskMitigation/PBN__RiskMitigation_3066)

## Property: has_RiskName

Limited treatment options and control measures without effective drugs.

## Property: has_RiskDescription

Efforts are being made to develop effective drugs for the treatment of COVID-19.

## Property: has_RiskSource

* [wu_current_2021](../Article/PBN__Article_118)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

